m+Medelevator.RU
← Поиск публикаций
Molecular psychiatry · 2026

Synaptic correlates of benzodiazepine tolerance.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Piot Alexandre, Jovanovic Jasmina N

Аннотация

Benzodiazepines are among the most widely prescribed psychotropic agents, exhibiting anxiolytic, hypnotic, anticonvulsant, and myorelaxant properties primarily mediated through positive allosteric modulation of type A γ-aminobutyric acid receptors (GABAARs)-the principal inhibitory receptors in the mammalian brain. However, prolonged benzodiazepine administration frequently results in the development of tolerance, a phenomenon characterized by reduced pharmacological efficacy and the need for escalating doses to sustain therapeutic benefit. Accumulating evidence indicates that benzodiazepine tolerance arises from complex neuroadaptive processes that induce long-lasting reorganization of neural circuits regulating stress responsiveness, arousal, and reward processing. In this review, we synthesize current knowledge on the clinical and societal impact of benzodiazepine use, delineate the molecular targets and mechanisms underlying their psychotropic effects on brain physiology and behaviour, and provide a comprehensive overview of the molecular and cellular adaptations contributing to benzodiazepine tolerance and withdrawal. Particular emphasis is placed on how prolonged exposure remodels inhibitory and excitatory synaptic organization. Furthermore, we examine evidence for benzodiazepine-induced synaptic adaptations in patients and highlight the potential of integrative in vivo imaging approaches to elucidate these processes within the complexity of the human brain. Finally, we propose that advancing these research avenues could foster a paradigm shift in the clinical use of benzodiazepines and guide the development of next-generation therapeutics with improved safety and efficacy profiles.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты